Safilens: European patent for hyaluronic acid release in lenses

“Now that we have finally achieved this patent we can demonstrate that Safilens is aware that the growth of the company also depends on the ability to invest constantly in research and innovation” said Safilens president Fernando Garbellotto. “The work has allowed us to focus our energies on the product, applied innovation and processes.”

The European patent is a goal that has been achieved 4 years after the first presentation of the innovative hyaluronic acid technology that enables all contact lens wearers to maintain and restore the pseudomucinous volume of lacrimal film to guarantee long-lasting comfort and wellbeing. To corroborate this thesis, we quote the patent, which is valid in about thirty countries in Europe, including Italy, France, Great Britain, Spain, Holland, Denmark and Germany.

“A contact lens is composed of a solid component, which gives the lens shape and structure and, in part, holds a liquid component which fosters compatibility between the lens and the wearer’s eye and includes a solution which substitutes tears”

It is known that an insufficient amount of lacrimal film – or a change in its quality – is the most frequent condition that can cause disorders and discomfort when using contact lenses. For this reason, Safilens has studied and produced a revolutionary lens in which the hydrophilic component is substituted with JALURONATE – GEL, a natural, hyaluronic acid-based biopolymer, in the Safe Gel 7 Days and Safe Gel 1 Day contact lenses and the more recent Safe Gel Toric 1 day lenses for astigmatism. It guarantees constant and unaltered tear production as well as a balanced supply of oxygen.
This step ahead in the research and production of quality lenses confirms Safilens as one of the main Eurpean players in the ophthalmic sector.